PMGC Holdings Inc.

(NASDAQ:ELAB) shares are trading higher on Friday as the company is advancing its engineered probiotic platform.

Details PMGC Holdings' subsidiary NorthStrive Biosciences Inc. announced plans to initiate an independent flow cytometry study to further characterize its engineered probiotic candidate, EL-22.

This study aims to quantify myostatin antigen expression on Lactobacillus casei, which is designed to help preserve muscle during weight loss treatments, including those involving GLP-1 receptor agonists.

The independent analysis will support comparability against materials previously manufactured by MOA Life Plus Co.